OBJECTIVES: To describe a novel extended-spectrum oxacillinase, named OXA-145, differing from narrow-spectrum OXA-35 (from the OXA-10 group) by deletion of residue Leu-165. The genetic environment of bla(OXA-145) and the biochemical properties of OXA-145 are reported. We also assessed the impact of the Leu-165 deletion on the hydrolysis spectrum of the ancestor OXA-10. METHODS: Extended-spectrum β-lactamase OXA-145 was identified in the multidrug-resistant clinical Pseudomonas aeruginosa 08-056, and characterized by isoelectric focusing, PCR and DNA sequencing. Antibiotic susceptibility tests were performed by agar dilution. The resistance profiles conferred by cloned bla(OXA-10), bla(OXA-35), bla(OXA-145) and a bla(OXA-10) derivative obtained by site-directed mutagenesis were determined in Escherichia coli. Kinetic parameters of OXA-35 and OXA-145 were established after purification of His-tagged proteins. RESULTS: The sequence of OXA-145, encoded by a class 1 integron-borne gene in strain 08-056, differed from that of narrow-spectrum penicillinase OXA-35 by a single amino acid deletion (Leu-165) located in the highly conserved omega loop. Deletion of Leu-165 from OXA-35 (yielding OXA-145) or OXA-10 (the progenitor of OXA-35) extended the hydrolysis spectrum to third-generation cephalosporins and to monobactams, while reducing that for penicillins. OXA-145 showed biphasic hydrolysis curves for all the substrates tested. Its activity against nitrocefin was 10-fold higher in the presence of sodium hydrogen carbonate. CONCLUSIONS: OXA-145 is a new extended-spectrum β-lactamase from the OXA-10 group. The deletion of Leu-165 is responsible for a shift in the hydrolysis spectrum from penicillins to third-generation cephalosporins, as well as monobactams. The loss of penicillin hydrolysis was due to a non-carboxylated Lys-73.
OBJECTIVES: To describe a novel extended-spectrum oxacillinase, named OXA-145, differing from narrow-spectrum OXA-35 (from the OXA-10 group) by deletion of residue Leu-165. The genetic environment of bla(OXA-145) and the biochemical properties of OXA-145 are reported. We also assessed the impact of the Leu-165 deletion on the hydrolysis spectrum of the ancestor OXA-10. METHODS: Extended-spectrum β-lactamase OXA-145 was identified in the multidrug-resistant clinical Pseudomonas aeruginosa 08-056, and characterized by isoelectric focusing, PCR and DNA sequencing. Antibiotic susceptibility tests were performed by agar dilution. The resistance profiles conferred by cloned bla(OXA-10), bla(OXA-35), bla(OXA-145) and a bla(OXA-10) derivative obtained by site-directed mutagenesis were determined in Escherichia coli. Kinetic parameters of OXA-35 and OXA-145 were established after purification of His-tagged proteins. RESULTS: The sequence of OXA-145, encoded by a class 1 integron-borne gene in strain 08-056, differed from that of narrow-spectrum penicillinase OXA-35 by a single amino acid deletion (Leu-165) located in the highly conserved omega loop. Deletion of Leu-165 from OXA-35 (yielding OXA-145) or OXA-10 (the progenitor of OXA-35) extended the hydrolysis spectrum to third-generation cephalosporins and to monobactams, while reducing that for penicillins. OXA-145 showed biphasic hydrolysis curves for all the substrates tested. Its activity against nitrocefin was 10-fold higher in the presence of sodium hydrogen carbonate. CONCLUSIONS:OXA-145 is a new extended-spectrum β-lactamase from the OXA-10 group. The deletion of Leu-165 is responsible for a shift in the hydrolysis spectrum from penicillins to third-generation cephalosporins, as well as monobactams. The loss of penicillin hydrolysis was due to a non-carboxylated Lys-73.
Authors: Emma C Schroder; Zachary L Klamer; Aysegul Saral; Kyle A Sugg; Cynthia M June; Troy Wymore; Agnieszka Szarecka; David A Leonard Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191
Authors: Joshua M Mitchell; Jozlyn R Clasman; Cynthia M June; Kip-Chumba J Kaitany; James R LaFleur; Magdalena A Taracila; Neil V Klinger; Robert A Bonomo; Troy Wymore; Agnieszka Szarecka; Rachel A Powers; David A Leonard Journal: Biochemistry Date: 2015-03-02 Impact factor: 3.162
Authors: Kip-Chumba J Kaitany; Neil V Klinger; Cynthia M June; Maddison E Ramey; Robert A Bonomo; Rachel A Powers; David A Leonard Journal: Antimicrob Agents Chemother Date: 2013-07-22 Impact factor: 5.191
Authors: Fátima Galán-Sánchez; Germán Bou; Antonio Oliver; Jorge Arca-Suárez; Pablo Fraile-Ribot; Juan Carlos Vázquez-Ucha; Gabriel Cabot; Marta Martínez-Guitián; Emilio Lence; Concepción González-Bello; Alejandro Beceiro; Manuel Rodríguez-Iglesias Journal: Antimicrob Agents Chemother Date: 2019-09-23 Impact factor: 5.191
Authors: Noellie Gay; Olivier Belmonte; Jean-Marc Collard; Mohamed Halifa; Mohammad Iqbal Issack; Saindou Mindjae; Philippe Palmyre; Abdul Aziz Ibrahim; Harena Rasamoelina; Loïc Flachet; Laurent Filleul; Eric Cardinale Journal: Front Public Health Date: 2017-07-06